4Wolfsen HC. Present status of photodynamic therapy for high- grade dysplasia in Barrett's esophagus. J Clin Gastroenterol, 2005,39 : 189-202.
5Burkle A. Physiology and pathophysiology of poly(ADP-ribosyl)ation. Bioessays,2001,23 :795-806.
6Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol, 2002,97 : 1888-1895.
7Ormsby AH, Vaezi MF, Richter JE, et al. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology ,2000,119:683-690.
8Mohammed IA, Streutker C J, Riddell RH. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. Mod Pathol,2002,15: 611-616.
9Yim HJ, Lee SW, Choung RS, et al. Is cytokeratin immunoreactivity useful in the diagnosis of short-segment Barrett's oesophagus in Korea? Eur J Gastroenterol Hepatol,2005 ,17 :611-616.
10Clemons NJ, McColl KE, Fitzgerald RC. Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology, 2007,133 : 1198-1209.
